We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current HPC market cap is 3.45M. The company's latest EPS is USD -0.0306 and P/E is -0.33.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.96M | 6.57M | 6.13M | 9.1M | 10.04M |
| Operating Income | -3.4M | -485k | -7.5M | -10.7M | -7.74M |
| Net Income | -3.43M | -744k | -8.95M | -10.61M | -8.1M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 4.2M | 4.45M | 15.31M | 10.39M | 6.69M |
| Total Liabilities | 1.81M | 2.44M | 2.08M | 6.41M | 7.05M |
| Total Equity | 2.39M | 2M | 13.23M | 3.98M | -358k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -2.78M | -3.86M | -8.08M | -9.75M | -5.73M |
| Investing | -20k | 2.73M | N/A | N/A | N/A |
| Financing | 3.04M | N/A | 17.03M | 4.08M | 2.72M |
| Market Cap | 3.45M |
| Price to Earnings Ratio | -0.33 |
| Price to Sales Ratio | 0.26 |
| Price to Cash Ratio | 1.45 |
| Price to Book Ratio | -7.41 |
| Dividend Yield | - |
| Shares Outstanding | 265.14M |
| Average Volume (1 week) | 114.24k |
| Average Volume (1 Month) | 155.59k |
| 52 Week Change | -80.60% |
| 52 Week High | 0.068 |
| 52 Week Low | 0.012 |
| Spread (Intraday) | 0 (13.33%) |
| Company Name | Hyrdation Pharmaceuticals Company Ltd |
| Address |
level 42 melbourne, victoria 3000 |
| Website | https://hydralyte.com |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
